한글목차

세계의 식물 유래 API(Plant Based API) 시장은 천연 및 지속 가능한 제품 소비자 수요가 증가함에 따라 눈부신 성장이 예상됩니다.

많은 소비자들은 사용하는 제품이 환경에 미치는 영향을 의식하게 되어 자연스럽고 지속 가능한 대체품을 요구하게 되었습니다. 그 결과, 많은 제약회사들이 이 수요에 부응하여 시장 차별화를 도모하기 위해 식물 유래 API에 눈을 돌리게 되어, 세계의 식물 유래 API 시장 성장을 지지하고 있습니다.

식물 유래 API 관심 증가

전통 의학은 오랫동안 식물 치유력에 의존하고 있으며, 이러한 많은 자연 요법이 광범위한 질병 치료에 효과적임을 보여줍니다. 그 결과, 식물 유래 API 개발 관심이 높아지고 있으며, 식물 유래 API은 이 동향의 중요 요소가 됩니다. 그 결과, 다양한 식물 유래 API이 개발되어 세계의 식물 유래 API 시장 성장을 견인하고 있습니다. 예를 들어 2018년 미국 식품약국(FDA)은 대마초 식물에 함유된 화합물인 칸나비디올(CBD)로 만든 의약품인 Epidiolex를 승인했습니다. 이 의약품은 2세 이상 환자를 대상으로 레녹스 가스트 증후군과 도라베 증후군이라는 두 가지의 드문 간질 치료에 사용됩니다. 에피디올렉스 승인은 서양 의학 식물 유래 API 사용 중요 이정표가 되었습니다. 마찬가지로 2020년 FDA는 담배로만든 단클론항체인 Sutimlimab을 한랭 응집소병(CAD) 성인 환자 용혈 치료제로 승인했습니다. Sutimlimab은 식물 유래 단클론항체로서 최초로 FDA 승인을 받은 것으로, 희귀질환 치료에 식물 유래 API을 사용하는데 있어서 큰 전진입니다. 게다가 2020년, FDA는 수혈성 철 과잉증 환자 치료에 사용되는 철 킬레이트제 Ferriprox를 승인했습니다. Ferriprox는 황열병 나무로 불리는 식물 유래된 Dephelipron이라는 식물 유래 화합물로 만들어집니다. Ferriprox 승인은 사라 세미아, 겸상 적혈구 빈혈 및 기타 혈액 질환 환자 발견되는 수혈성 철분 과다증 환자에게 새로운 치료 옵션을 제공할 전망입니다.

식물 기반 제품 수요가 증가함에 따라 식물 기반 의약품 관심이 높아졌으며 식물 기반 의약품 활성 성분 수요도 확실히 증가하여 세계의 식물 기반 API 시장 성장을 지원하고 있습니다.

만성 질환 유병률 증가

암, 당뇨병, 심장병 등의만성 질환은 증가하는 경향이 있으며 새로운 효과적인 치료법 필요성이 높아지고 있습니다. 식물 유래 API는 항염증 및 항산화 작용과 같은 광범위한 건강상 이점이 있는 것으로 나타났으며, 다양한 의약품 제조에 사용됩니다. 그 결과, 이러한 만성 질환 치료에 사용되는 몇몇 의약품 및 치료법 식물 유래 버전이 출시되어 향후 수년간 세계의 식물 유래 API 시장 성장에 새로운 전망이 탄생하고 있습니다. 예를 들어 파클리탁셀은 유방암, 난소암, 폐암 등 다양한 암 치료에 이용되는 화학요법약입니다. 2020년 인도 파클리탁셀 식물 유래 버전이 출시되었습니다. 이 식물 유래 버전은 청록 나무로만들어졌으며 수세기에 걸쳐 다양한 질병을 치료하는 데 사용되었습니다. 파클리탁셀 식물 유래 버전은 재생 가능한 자원을 사용하여 생산되기 때문에 기존 합성 버전보다 지속 가능하다고 생각됩니다. 마찬가지로, 디곡신은 심부전이나 특정 심장 박동 장애를 치료하는 데 사용되는 약물입니다. 2021년, 식물 유래 디곡신이 인도에서 발매되었습니다. 이 식물 유래 버전은 수세기에 걸쳐 전통 의료 사용되어 온 디기타리스 라나타라고 불리는 식물로 만들어졌습니다. 디곡신 식물 유래 버전은 석유화학제품을 사용하여 생산되는 합성 버전보다 지속 가능한 대안으로 간주됩니다.

생명공학과 유전체학 진보

유전체학과 생명공학 발전은 식물 활성 화합물 생산을 담당하는 특정 유전자 확인과 분리를 가능하게 했습니다. 이에 따라 활성 화합물을 대량으로 생산하는 새로운 식물 품종이 개발되어 새로운 식물 유래 API 개발에 이용할 수 있게 되어, 세계의 식물 유래 API 시장 성장을 지지하고 있습니다. 이것은 또한 이 분야에 투자를 하는 세계의 다양한 크고 작은 기업들 관심을 끌고 있으며, 따라서 세계의 식물 유래 API 시장 성장을 지원합니다. 예를 들어 이스라엘 바이오 기업인 Kaiima Bio-Agritech는 고가치 식물 유래 API를 생산하기 위한 작물 유전자 개선을 위한 플랫폼을 개발하고 캐나다 바이오 기업인 Ceapro는 의약품 및 기타 제품에 사용 식물 활성 성분 추출을 위한 독특한 기술을 개발했습니다.

사용 가능한 사용자 정의

TechSci Research는 특정 시장 데이터를 사용하여 기업 고유 요구에 맞게 사용자 정의를 제공합니다. 보고서는 다음을 사용자 정의할 수 있습니다.

기업 정보

• 추가 시장 기업(최대 5개사) 상세 분석 및 프로파일링

목차

제1장 주요 요약

• 시장 정의
• 시장 범위
  • 대상 시장
  • 조사 대상년도
  • 주요 시장 세분화

제2장 조사 방법

• 조사 목적
• 기준 방법론
• 주요 산업 파트너
• 주요 협회와 2차 정보원
• 예측 기법
• 데이터 삼각측량과 검증
• 가정과 한계

제3장 주요 요약

• 시장 주요 요약
• 주요 시장 세분화 주요 요약
• 주요 시장 기업 주요 요약
• 주요 지역/국가 주요 요약
• 시장 성장 성장 촉진 요인, 과제 및 동향 주요 요약

제4장 고객 의견

제5장 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 지역별
  • 기업별
• 제품 맵
  • 유형별
  • 용도별
  • 지역별

제6장 북미 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 국가별
• 북미별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 국가별
• 유럽 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 국가별
• 아시아태평양 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액 기준
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 국가별
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카 식물 유래 API 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 국가별
• MEA : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진 요인
• 과제

제12장 시장 동향과 발전

• 최근 전개
• 합병, 인수
• 제품 발표

제13장 세계의 식물 유래 API 시장 SWOT 분석

제14장 포터의 5세력 분석

• 업계 내 경쟁
• 신규 진입 가능성
• 공급자 힘
• 고객 힘
• 대체품 위협

제15장 경쟁 구도

• Business Overview
• Product Offerings
• Recent Developments
• Key Personnel
• SWOT Analysis
  • Roquette Freres SA
  • EVONIK Industries, AG
  • Cargill, Inc.
  • Kothari Phytochemicals& Industries Ltd
  • Medipure Pharmaceuticals Inc.
  • Centroflora Group
  • Arboris, LLCs
  • BASF SE
  • Novartis AG
  • Sanofi SA
  • GlaxoSmithKline, plc
  • F. Hoffmann-La Roche AG

제16장 전략 제안

영문목차

Global Plant Based API Market is expected to grow at an impressive rate during the forecast period on account of the growing consumer demand for natural and sustainable products. Many consumers are becoming more conscious of the environmental impact of the products they use and are increasingly seeking out natural and sustainable alternatives. As a result, many pharmaceutical companies are now turning to plant-based APIs to meet this demand and differentiate themselves in the market, thereby supporting the growth of global plant based API market.

Plant-based APIs are derived from natural sources, such as herbs, spices, and other plants, and are used to produce a wide range of pharmaceuticals, including antibiotics, painkillers, and anticancer drugs. The growing demand for eco friendly products and need to achieve sustainability goals among countries and governments worldwide will create lucrative opportunities for the growth of global plant based API market in the next few years.

Another driver of the global plant-based API market is the growing interest in plant-based medicines. Traditional medicine has long relied on the healing properties of plants, and many of these natural remedies have been shown to be effective in treating a wide range of ailments. As a result, there is growing interest in the development of plant-based medicines, and plant-based APIs are a key component of this trend.

Growing Interest in Plant Based Medicines

Traditional medicine has long relied on the healing properties of plants, and many of these natural remedies have been shown to be effective in treating a wide range of ailments. As a result, there is a growing interest in the development of plant-based medicines, and plant-based APIs are a key component of this trend. This has in turn led to the development of various plant based pharmaceuticals thereby driving the growth of global plant based active pharmaceutical ingredient (API) market. For instance, in 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex, a drug made from cannabidiol (CBD), a compound found in the cannabis plant. This drug is used to treat two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. The approval of Epidiolex marked a significant milestone in the use of plant-based pharmaceuticals in Western medicine. Similarly, in 2020, the FDA approved Sutimlimab, a monoclonal antibody made from tobacco plants, for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab is the first plant-based monoclonal antibody to receive FDA approval, and it is a significant step forward in the use of plant-based pharmaceuticals for the treatment of rare diseases. Additionally, in 2020, the FDA approved Ferriprox, an iron chelator used to treat patients with transfusional iron overload. Ferriprox is made from a plant-based compound called deferiprone, which is derived from a plant called the yellow fever tree. The approval of Ferriprox provides a new treatment option for patients with transfusional iron overload, which can occur in patients with thalassemia, sickle cell anemia, and other blood disorders.

The increasing interest in plant based pharmaceuticals along with growing demand for plant based products will certainly increase the demand for plant based active pharmaceutical ingredients as well, thereby supporting the growth of global plant based API market.

Increasing Prevalence of Chronic Diseases

Chronic diseases such as cancer, diabetes, and heart disease are on the rise, and there is a growing need for new and effective treatments. Plant based APIs have been shown to have a wide range of health benefits, including anti-inflammatory and antioxidant properties, and are being used to produce a wide range of pharmaceuticals. This has in turn contributed to the launch of plant based versions of several medicine or therapies that are used to treat these chronic conditions, thereby creating new prospects for the growth of global plant based API market in the next few years. For instance, Paclitaxel is a chemotherapy drug used to treat various cancers, including breast, ovarian, and lung cancer. In 2020, a plant-based version of paclitaxel was launched in India. This plant-based version is made from yew trees, which have been used for centuries to treat various ailments. The plant-based version of paclitaxel is considered to be more sustainable than the traditional synthetic version, as it is produced using renewable resources. Similarly, Digoxin is a medication used to treat heart failure and certain heart rhythm disorders. In 2021, a plant-based version of digoxin was launched in India. The plant-based version is made from a plant called Digitalis lanata, which has been used in traditional medicine for centuries. The plant-based version of digoxin is seen as a more sustainable alternative to the synthetic version, which is produced using petrochemicals.

Advances in Biotechnology and Genomics

The advancement in genomics and biotechnology has enabled the identification and isolation of specific genes responsible for the production of active compounds in plants. This has led to the development of new plant varieties that produce higher quantities of active compounds, which can be used to develop new plant-based APIs, thereby supporting the growth of global plant based API market. This has also attracted the focus of various small and big companies worldwide making investment into this space and hence supporting the growth of global plant based API market. For example, Israeli biotech company Kaiima Bio-Agritech has developed a platform for the genetic improvement of crops for the production of high-value plant-based APIs, while Canadian biotech company Ceapro has developed a proprietary technology for the extraction of active ingredients from plants for use in pharmaceuticals and other products.

Market Segmentation

Global Plant Based API Market can be segmented by type, by application, and by region. Based on type, the Global Plant Based API market can be categorized into alkaloids, anthocyanins, flavonoids, phenolic acids, terpenoids, lignans and stilbenes, and others. By application, the Global Plant Based API market can be fragmented into pharmaceuticals, nutraceuticals, herbal based industries, and others. Regionally, the Global Plant Based API market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Roquette Freres SA, EVONIK Industries, AG, Cargill, Inc., Kothari Phytochemicals & Industries Ltd, Medipure Pharmaceuticals Inc., Centroflora Group, Arboris, LLCs, BASF SE, Novartis AG, Sanofi SA, GlaxoSmithKline, plc, F. Hoffmann-La Roche AG, among others are some of the leading players operating in the Global Plant Based API market.

Recent Developments

• In 2019, a team of researchers from the University of Wisconsin-Madison developed a new platform for producing plant-based APIs using genetically modified tobacco plants. The researchers were able to produce an anti-inflammatory protein called Interleukin-37 (IL-37) in tobacco plants and demonstrated that the protein was able to alleviate symptoms of inflammatory bowel disease in mice.
• In 2019, Sanofi SA announced a USD 640 million (€600 million) investment in its French production sites, with a focus on plant-based APIs for the treatment of rare diseases. The investment will support the development of new plant-based technologies, including the use of algae and other microorganisms to produce APIs. Sanofi has also invested in the production of plant-based insulin, which was approved by the FDA in 2020.
• Novartis has also made significant investments in plant-based APIs in recent years, with a focus on the use of plant cell culture technology. In 2020, Novartis announced a collaboration with Canadian biotech company PlantForm Corporation to develop plant-based biosimilars for the treatment of rare diseases. Novartis has also invested in the development of plant-based vaccines, including a collaboration with Boston-based biotech company VBI Vaccines to develop a plant-based vaccine for COVID-19.
• In 2020, Amyris, a California-based biotechnology company, announced that it had successfully produced a plant-based version of the anti-malarial drug artemisinin. The company used a proprietary yeast strain to produce the drug, which was then licensed to pharmaceutical companies for further development and commercialization.
• In 2021, researchers from the University of Bristol developed a method for producing a key component of the malaria drug artemisinin using genetically modified yeast. This approach offers a more sustainable and cost-effective alternative to traditional methods of producing the drug, which involve extracting it from the artemisia plant

Report Scope:

In this report, Global Plant Based API Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Plant Based API Market, By Type:

• Alkaloids
• Anthocyanins
• Flavonoids
• Phenolic Acids
• Terpenoids
• Lignans and Stilbenes
• Others

Plant Based API Market, By Application:

• Pharmaceuticals
• Nutraceuticals
• Herbal Based Industries
• Others

Plant Based API Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Plant Based API Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plant Based API Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Alkaloids, Anthocyanins, Flavonoids, Phenolic Acids, Terpenoids, Lignans and Stilbenes, Others)
  • 5.2.2. By Application (Pharmaceuticals, Nutraceuticals, Herbal Based Industries, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Plant Based API Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Plant Based API Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Plant Based API Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Plant Based API Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Plant Based API Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Plant Based API Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Plant Based API Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Plant Based API Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Plant Based API Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Plant Based API Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Plant Based API Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Plant Based API Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Plant Based API Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Plant Based API Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Plant Based API Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Plant Based API Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Plant Based API Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Plant Based API Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Plant Based API Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Plant Based API Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Plant Based API Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Plant Based API Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Plant Based API Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Plant Based API Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Plant Based API Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Roquette Freres SA
  • 15.5.2. EVONIK Industries, AG
  • 15.5.3. Cargill, Inc.
  • 15.5.4. Kothari Phytochemicals & Industries Ltd
  • 15.5.5. Medipure Pharmaceuticals Inc.
  • 15.5.6. Centroflora Group
  • 15.5.7. Arboris, LLCs
  • 15.5.8. BASF SE
  • 15.5.9. Novartis AG
  • 15.5.10. Sanofi SA
  • 15.5.11. GlaxoSmithKline, plc
  • 15.5.12. F. Hoffmann-La Roche AG

16. Strategic Recommendations